Evidence map›Paper›PMID 37631349›Full record

ArticlePharmaceutics2023

Multilocus Genetic Profile Reflecting Low Dopaminergic Signaling Is Directly Associated with Obesity and Cardiometabolic Disorders Due to Antipsychotic Treatment.

Aurora Arrue, Olga Olivas, Leire Erkoreka, Francisco Jose Alvarez, Ainara Arnaiz, Noemi Varela, Ainhoa Bilbao, Jose-Julio Rodríguez, María Teresa Moreno-Calle, Estibaliz Gordo and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Aurora ArrueMental Health Network Group, BioCruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0002-9173-6229
Olga OlivasMental Health Network Group, BioCruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Leire ErkorekaMental Health Network Group, BioCruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Francisco Jose AlvarezResearch Unit, Cruces University Hospital, Osakidetza Basque Health Service, 48903 Barakaldo, Spain.
Ainara ArnaizMental Health Network Group, BioCruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Noemi VarelaMental Health Network Group, BioCruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Ainhoa BilbaoAnimal Research Facility, BioCruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Jose-Julio RodríguezDepartment of Neurosciences, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU, 48940 Leioa, Spain.
María Teresa Moreno-CalleMental Health Network Group, BioCruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Estibaliz GordoBizkaia Mental Health Network, Zamudio Hospital, Osakidetza Basque Health Service, 48170 Zamudio, Spain.
Elena MarínMental Health Network Group, BioCruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0002-3712-2883
Javier Garcia-CanoAlternatives to Hospitalization in Bilbao, Bizkaia Mental Health Network, Osakidetza Basque Health Service, 48903 Bilbao, Spain.
Estela SaezMental Health Network Group, BioCruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Miguel Ángel Gonzalez-TorresDepartment of Neurosciences, Faculty of Medicine and Dentistry, University of the Basque Country UPV/EHU, 48940 Leioa, Spain.
Mercedes ZumárragaMental Health Network Group, BioCruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Nieves BasterrecheFunctional Neuroanatomy, BioCruces Bizkaia Health Research Institute, Ikerbasque Basque Foundation for Science, 48903 Barakaldo, Spain.
BioCruces Health research Institute · ESOsakidetza · ESIkerbasque · ESUniversity of the Basque Country · ES

Funding

Basque Government PI 2011111088 and PI 2018111093.
6 · The paper itself

Abstract

Treatment with second-generation antipsychotics (SGAs) can cause obesity and other cardiometabolic disorders linked to D2 receptor (DRD2) and to genotypes affecting dopaminergic (DA) activity, within reward circuits. We explored the relationship of cardiometabolic alterations with single genetic polymorphisms

Indexed as

atypical antipsychoticcardiometabolic disordersdopaminergic systemmultilocus genetic profile scorepolymorphisms

Identifiers

PMID37631349
PMCPMC10459305
OpenAlexW4385795916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.